Live Feeds
● LIVE Updated 1h ago · 27 sources tracked

Germany's Merck boosts life sciences business with $11 billion bet on Bio-Techne

German drugmaker Merck KGaA has agreed to buy U.S.-based Bio-Techne in an all-cash deal. The acquisition aims to expand Merck's leadership in life sciences, specifically in drug discovery and gene therapy. This represents the company's largest deal in over a decade.

RSS Source map (25)

What changed

Merck KGaA announced the $11.3 billion acquisition of Bio-Techne to boost its life sciences business.

Live updates

  1. Merck KGaA to Acquire Bio-Techne for $11.3 Billion

    German drugmaker Merck KGaA has agreed to buy U.S.-based Bio-Techne in an all-cash deal. The acquisition aims to expand Merck's leadership in life sciences, specifically in drug discovery and gene therapy. This represents the company's largest deal in over a decade.

    What's confirmed:

    • Merck KGaA agreed to acquire U.S. biotech firm Bio-Techne for $11.3 billion.
    • The transaction is an all-cash deal.
    • This is Merck KGaA's largest deal in more than a decade.
    • Bio-Techne is based in Minneapolis, Minnesota.
    • The acquisition targets growth in life sciences, drug discovery, and gene therapy.
    • Bio-Techne shares rose 20% following the merger news.

    Still unconfirmed:

    • The deal is expected to produce 140 million euros in synergies by the third year.
    • Bio-Techne possesses 500,000 products.
    • This is the largest deal for Merck KGaA since the 2015 Sigma-Aldrich purchase.
    confidence 95%